European Monitoring Centre for Drugs and Drug Addiction
12
World Health Organisation (WHO)
11
IACAPAP
9
et al.
8
Organización Mundial de la Salud OMS
6
Ministry of Health, Rwanda
5
Organisation Mondiale de la Santé OMS
5
WHO
5
Drugs for Neglected Diseases initiative DNDi
4
Indian Council of Medical Research (ICMR)
4
Ministry of Health and Social Services (MOHSS)
4
Ministry of Health, Kenya
4
OPAS
4
Organisation mondiale de la Santé
4
Organisation Mondiale de la Santé OMS
4
Pan American Health Organisation PAHO
4
Pan American Health Organization
4
Africa CDC
3
C. Carandang
3
C. Gray
3
H. Marval-Ospino
3
United Nations Office on Drugs and Crime
3
Wiedenmayer, K. et al.
3
Africa CDC Centres for Disease Control and Prevention
2
Africa Center for Disease Control and Prevention
2
African Union
2
C. Bachmann
2
Centers for Disease Control and Prevention CDC
2
European Union
2
Ministerio de Salud Argentina
2
Ministerio de Salud Chile
2
Ministerio de Salud Pública y Bienestar Social Paraguay
2
Ministry of Health and Sanitation Sierra Leone
2
Ministry of Health, Gabarone, Botswana
2
National Centre for Disease Control (NCDC)
2
National Vector Borne Disease Control Programme (NVBDCP)
2
Organisation de la Santé Mondiale
2
Organización Mundial de Saude and OPAS
2
Pharmacy Board Sierra Leone
2
Republic of Kenya, Ministry of Health
2
Robert-Koch-Institut RKI
2
S. MacPhee
2
T. Lempp
2
United Nations
2
United Nations Office on Drug and Crime UNODC
2
Zambia Medicines Regulatory Authority (ZAMRA)
2
2012
1
2016
1
A. K. Lam
1
A. Martin
1
A. Smajljaj
1
A. Sondheimer
1
A. Sönnerborg
1
A. Xhuvani
1
A.Ramesh
1
Abdulrahim, D.
1
ACCSI, et al.
1
Adrian Sondheimer
1
Agence Japonaise de Cooperation International Kokusai Kogyo Co., Ltd.
1
Agency for Toxic Substances & Disease Registry
1
AIEPI Hospitalario
1
American Chemistry Council
1
and O. Bowden-Jones
1
ANDEMIA
1
Australian National Clinical Evidence Taskforce
1
Berkley, James A.
1
BioNTech
1
Bolivia, Ministerio de Salud, Gobierno de Estado Plurinacional s
1
Bundeszentrale für gesundheitliche Aufklärung
1
Butkus, R. A.
1
Butterworth Heinemann
1
C. Giannou, M. Baldan and A. Molde
1
C. Kalpaki, M. Moudatsou, E. Maraki, et al.
1
Centers for Disease Control and Prevention (CDC)
1
Centre Anti Poison du Maroc
1
Centre d’excellence Africain pour la santé de la Mère et de l’enfant (CEA-SAMEF)
1
Centre for Antibiotic Resistance Research (CARe), University of Gothenburg
1
Chatanga, Peter
1
Chișinău
1
CODEVIDA, Coalición de Organizaciones por el Derecho a la Salud y a la Vida
1
Congressional Research Service
1
Cordner, S.
1
Cureus
1
D. de Lange, D. Radeloff
1
D. Raben
1
D. Radeloff
1
D.de Lange
1
Dadvand, P.
1
Damialis, A.
1
DATER House
1
David P.M., Le Dévédec N. et al.
1
Dermatol Venez, Univerisdad Central de Venezuela
1
Deutsche Hauptstelle für Suchtfragen e.V.
1
Dilys Morgan, Hilary Kirkbride and Bengü Said
1
Directorate General of Health Services Ministry of Health & Family Welfare Government of the People’s Republic of Bangladesh
1
Dr. X. Zeka
1
Drug Safety Monitoring Programme
1
Drugs Advisory Board, Republic of Botswana (Gabarone, Botswana)
1
DTG
1
E. Gjergji
1
E. Subata
1
Elsevier Ltd.
1
EMCDDA
1
et al
1
Europäische Beobachtungsstelle für Drogen und Drogensucht (EMCDDA)
1
European Centre for Disases Prevention and Control ECDC
1
European Scientific Journal
1
F. Fezeu
1
Fairlamb, A.H.
1
Federal Ministries of Agriculture, Environment and Health
1
Food and Agriculture Organization (FAO)
1
Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO)
1
Food and Agriculture Organization of the United Nations FAO
1
Food and Drug Authority (FDA), Ghana
1
Food and Drugs Authority (FDA), Ghana
1
Food, Medicine and Health care Administration and Control Authority of Ethiopia (FMHACA)
1
Frewer, A.
1
Friedman, J.F. et al.
1
Fuller, R.
1
Gascon M., Markevych I.
1
GBD 2019 Blindness and Vision Impairment Collaborators
1
GBD 2019 Tuberculosis Collaborators
1
GBD2019 Dementia Forecasting Coolaborators
1
Global smart
1
Gobierno Bolivariano de Venezuela, UNICEF, et al.
1
Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals
1
Government of Kenya
1
Government of South Africa
1
Government of Tanzania
1
Gutiéerrez, J.
1
Gutiérrez, J.
1
H. Furtmayr, K. Krása
1
Haywood, A. and B. D Glass
1
Health Care without Harm
1
Horn, D.
1
Human Rights Watch
1
ICF International
1
ICRC
1
IFRC
1
Indian Council for Medical Research (ICMR)
1
Indian Council of Medical Research (ICMR) & Department of Biotechnology
1
Instituti Shendetit Public
1
International Bureau for Epilepsy
1
International Committee of the Red Cross ICRC
1
International Dairy Federation
1
International Federation of Medical Students’ Associations (IFMSA)
1
International League against Epilepsy
1
International Pharmaceutical Federation FIP
1
Iosue, S.
1
J Pharm Pharm Sci
1
J. M. Rey. M. Irarrázaval
1
J. O. Errecalde
1
J. Sekulić
1
J.-J. Kim
1
Jackson, J., Kheng Heng, L., Eklund, G. et al.
1
Joseph M Rey
1
Kadam. A.
1
Katrin Leitmeyer
1
Kingdom of Swaziland Ministry of Health
1
Koren, H.
1
L'avoisier
1
L. Savikj
1
Laboratorio Central de Salud Publica
1
Liberia Medicines and Health Products Regulatory Authority (LMHRA)
1
Lisa Myers, Laura Theytaz-Bergman
1
M. Hodaj
1
M. Vitoriaa
1
Mapako, Tonderai, Simbarashe Rusakaniko, Maarten J. Postma, Marinus van Hulst, Janet Dzangare, Stellah Ngwende, John Mandisarisa, Ponesai Nyika, David A. Mvere, Owen Mugurungi, and Mufuta Tshimanga
1
Marie-Noel Bruné Drisse and Fiona Goldizen
1
Mario R Dal Poz, Neeru Gupta, Estelle Quain and Agnes LB Soucat
In preparing this paper, the Pharmacovigilance Group of the Pan American Health Organization’s Pan American Network for Drug Regulatory Harmonization (PANDRH) adopted the perspective of PAHO/WHO, which considers Pharmacovigilance, an essential component of public health programs. Its intention was... to facilitate the development of pharmacovigilance systems in the Region of the Americas and improve, strengthen, and promote the adoption of good practices to improve safety for patients and the general population, based on the needs of the Region.
Document also available in Spanish and Portuguese!more
The Agency for Toxic Substances and Disease Registry (ATSDR) has produced a three-volume series entitled Managing Hazardous Material Incidents. The series is designed to help emergency response and health care professionals plan for and respond to hazardous material emergencies.
- Volume I Emergenc...y Medical Services: A Planning Guide for the Management of Contaminated Patients
- Volume II Hospital Emergency Departments: A Planning Guide for the Management of Contaminated Patients
- Volume III Medical Management Guidelines for Acute Chemical Exposures
Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials.
Volume III is a guide for health care professionals who treat persons who have been exposed to hazardous materials. more
В этом дискуссионном документе излагаются факты, касающиеся передозировки опиоидов, мер, которые могут быть приняты в целях предупреждения и лечения (коррекции) п...редозировки опиоидов, и указываются области, требующие дальнейшего исследования.more
This report summarizes the latest scientific knowledge on the links between exposure to air pollution and adverse health effects in children. It is intended to inform and motivate individual and collective action by health care professionals to prevent damage to children’s health from exposure to ...air pollution. Air pollution is a major environmental health threat. Exposure to fine particles in both the ambient environment and in the household causes about seven million premature deaths each year. Ambient air pollution (AAP) alone imposes enormous costs on the global economy, amounting to more than US$ 5 trillion in total welfare losses in 2013.more
"The aim of this book remains as for the first edition, namely to provide an initial point of ready
reference for the identification of hazards and precautions for dangerous chemicals. It is targeted
not only at those in the chemical and process industries, but also anyone likely to work with
che...micals within industry and in the service sector, e.g. hospitals, universities, research laboratories,
engineering, agriculture, etc. "more
These guidelines have been developed to provide guidance to the Ministry of Health in managing applications for registration of human pharmaceutical products in Rwanda. It was compiled by the Technical Working Group (TWG) on Medicines Evaluation and Registration (MER) of the East African Community M...edicine Regulatory Harmonization (EAC MRH) Project. The group relied on their experiences and knowledge on medicines registration requirements of their individual Countries. World Health Organization (WHO) and the International Conference on Harmonization of Technical Requirements of Medicines for Human Use (ICH) and other available literature. more
This manual describes methods for investigating clusters or outbreaks that may be of chemical origin and describes the importance of a structured, coordinated, collaborative multidisciplinary, multi-agency approach at local, regional, national and international levels.
This update of the Guidelines for poison control, entitled Guidelines for establishing a poison centre, reflects the development of the role of poison centres in public health and the sound management of chemicals, described in section 1, and the opportunities provided by new technology. Assessments... carried out under the IHR show
continuing gaps in capacity for managing chemicals (2). In particular, many countries still lack access to poison
centre services (3). There is therefore demand for updated guidance.more
2nd edition. The purpose of the WHO human health risk assessment toolkit: chemical hazards is to provide its users with guidance to identify, acquire and use the information needed to assess chemical hazards, exposures and the corresponding health risks in their given health risk assessment contexts... at local and/or national levels.
The Toolkit provides road maps for conducting a human health risk assessment, identifies information that must be gathered to complete an assessment and provides electronic links to international resources from which the user can obtain information and methods essential for conducting the human health risk assessmentmore
The guideline on Drug misuse: opioid detoxification, commissioned by NICE and developed by the National Collaborating Centre for Mental Health, sets out clear, evidence-based recommendations for healthcare staff on how to work with people who misuse opioids to significantly improve their treatment a...nd care, and to deliver detoxification safely and effectively. Of the estimated 4 million people in the UK who use illicit drugs each year, approximately 50,000 misuse opioids (such as heroin, opium, morphine, codeine and methadone). Opioid misuse presents a considerable health risk and can lead to significant social problems. This NICE guideline is an important tool in helping people to overcome their drug problem.more
At the forefront of DNDi’s efforts to develop new treatments is the need to understand the realities and treatment needs of patients and health care staff in the field. The ultimate goal for human African trypanosomiasis (HAT) is a truly simplified
treatment which can be orally administered, impl...emented at the primary health care level, and effective against both stages of the disease.more
Full Perscribing information on Fexinidazole Tablet for oral use
INDICATIONS AND USAGE
Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati...ents 6 years of age and older and weighing at least 20 kg.
Limitations of Use
Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/μL) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there are no other available treatment options [see Warnings and Precautions (5.1)]more